Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4461998
Max Phase: Preclinical
Molecular Formula: C65H98N22O21S4
Molecular Weight: 1651.90
Molecule Type: Unknown
Associated Items:
ID: ALA4461998
Max Phase: Preclinical
Molecular Formula: C65H98N22O21S4
Molecular Weight: 1651.90
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)CN)C(=O)N[C@@H](CSSC[C@@H](C(N)=O)NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2
Standard InChI: InChI=1S/C65H98N22O21S4/c1-6-30(4)50-63(106)81-40(51(68)94)23-109-111-26-43-59(102)79-38(21-88)55(98)78-37(16-33-20-70-28-72-33)65(108)86-13-7-9-44(86)60(103)73-31(5)52(95)82-42(25-112-110-24-41(57(100)83-43)74-47(91)18-66)58(101)80-39(22-89)56(99)84-49(29(2)3)62(105)76-35(17-46(67)90)54(97)77-36(15-32-19-69-27-71-32)64(107)87-14-8-10-45(87)61(104)75-34(53(96)85-50)11-12-48(92)93/h19-20,27-31,34-45,49-50,88-89H,6-18,21-26,66H2,1-5H3,(H2,67,90)(H2,68,94)(H,69,71)(H,70,72)(H,73,103)(H,74,91)(H,75,104)(H,76,105)(H,77,97)(H,78,98)(H,79,102)(H,80,101)(H,81,106)(H,82,95)(H,83,100)(H,84,99)(H,85,96)(H,92,93)/t30-,31-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,49-,50-/m0/s1
Standard InChI Key: GLNHQLYIFATJOO-MOHPVCKVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1651.90 | Molecular Weight (Monoisotopic): 1650.6160 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Hone AJ, Fisher F, Christensen S, Gajewiak J, Larkin D, Whiteaker P, McIntosh JM.. (2019) PeIA-5466: A Novel Peptide Antagonist Containing Non-natural Amino Acids That Selectively Targets α3β2 Nicotinic Acetylcholine Receptors., 62 (13): [PMID:31194549] [10.1021/acs.jmedchem.9b00566] |
2. Hone AJ, Kaas Q, Kearns I, Hararah F, Gajewiak J, Christensen S, Craik DJ, McIntosh JM.. (2021) Computational and Functional Mapping of Human and Rat α6β4 Nicotinic Acetylcholine Receptors Reveals Species-Specific Ligand-Binding Motifs., 64 (3.0): [PMID:33523678] [10.1021/acs.jmedchem.0c01973] |
Source(1):